GLP-1 vs GLP-3: What's Real, What's Confused

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides and GLP-1 education

Searches for "GLP-1 vs GLP-3" reflect a common misunderstanding. GLP-1 is a real gut hormone and an established medication pathway. "GLP-3," however, is not an FDA-approved medication class, a standard clinical prescribing term, or the correct name for next-generation GLP-1 drugs as of May 2026. People searching for GLP-3 are often looking for information about dual agonists, triple agonists, GLP-2, or investigational medications such as retatrutide. This article explains what is real, what people may be searching for, and the upstream GLP-1 pathway genetics that matter for weight-management decisions.

"GLP-3" is not a recognized peptide or drug class

"GLP-3" is not a standard FDA-approved drug class or routine clinical term in obesity, diabetes, or incretin-based prescribing. GLP-1 and GLP-2 are real proglucagon-derived gut peptides with established biological roles. "GLP-3" searches most often reflect one of three real concepts: (a) the glucagon-receptor third arm of investigational triple agonists like retatrutide; (b) confusion with GLP-2, a real but separate peptide pathway used in niche clinical contexts such as short bowel syndrome; or (c) confusion with the dual GIP/GLP-1 biology of tirzepatide.

What people may actually mean: triple agonists

Investigational compounds like retatrutide are not "GLP-3" medications. Retatrutide is more accurately described as an investigational triple hormone receptor agonist designed to activate three receptor pathways: GIP, GLP-1, and glucagon. The "third arm" is glucagon receptor activity, not a separate GLP-3 hormone. Retatrutide remains investigational and is not FDA-approved as of May 2026. Lilly is studying it in clinical trials for obesity and overweight with weight-related conditions, type 2 diabetes, obstructive sleep apnea, osteoarthritis, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

What is FDA-approved in the GLP-1 space today

FDA-approved GLP-1 and incretin-pathway medications include drugs such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, depending on indication and brand. Semaglutide is used under different brands for type 2 diabetes, oral diabetes treatment, and chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist approved under Mounjaro for type 2 diabetes and under Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Retatrutide is different: it is not FDA-approved, is not commercially available, and should not be purchased online or used outside legitimate clinical-trial oversight.

Genetic context for the GLP-1 pathway

Whether the eventual prescription is a single-receptor GLP-1 agonist, a dual GIP/GLP-1 agonist, or a future approved multi-receptor agonist, variants in GLP1R and GIPR may help describe the upstream incretin biology. GLP1R encodes the GLP-1 receptor involved in appetite, satiety, insulin signaling, and gastric-emptying pathways. GIPR encodes the receptor for glucose-dependent insulinotropic polypeptide, which is relevant to dual-pathway medications like tirzepatide. FTO may influence appetite regulation and adiposity tendency, while MC4R is central to satiety signaling and energy balance. None of these variants predict response to any specific compound — they describe the metabolic terrain that a healthcare provider is working within.

PlexusDx offers weight-management protocols through its Weight Management Protocols, including Weight Management Protocols focused on GLP-1 and incretin-pathway decision support. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in GLP1R, GIPR, FTO, and MC4R that may shape baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into a more informed conversation with your healthcare provider.

Related reading on PlexusDx: GLP-1 Hormone, What Is GLP-1?, What Is GLP-1?, GLP-1 Receptor Agonist.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, determine medication eligibility, or predict response to any specific medication or peptide. Retatrutide is investigational and is not currently FDA-approved. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats inside the PlexusDx Weight Management Protocols collection, or start upstream with the Precision Peptide Genetic Test to understand your GLP-1 pathway biology before committing to a protocol.

Frequently Asked Questions

Is GLP-3 a real thing?

"GLP-3" is not a standard FDA-approved medication class or routine clinical prescribing term as of May 2026. GLP-1 and GLP-2 are real gut peptides; GLP-3 is usually a search-term misunderstanding. People searching for it often mean investigational triple agonists like retatrutide, the dual GIP/GLP-1 biology of tirzepatide, or the real but separate GLP-2 pathway.

What is retatrutide?

Retatrutide is an investigational triple hormone receptor agonist being developed by Eli Lilly. It is designed to activate GIP, GLP-1, and glucagon receptors. Retatrutide is not FDA-approved, is not commercially available, and legitimate access is limited to appropriate clinical-trial participation.

Should I wait for "GLP-3" before starting a GLP-1 medication?

There is no FDA-approved "GLP-3" medication to wait for. There are approved GLP-1 and GIP/GLP-1 medications available for specific indications, and there are investigational multi-receptor agonists still being studied. Whether to start a current FDA-approved protocol or consider clinical-trial options is a clinical decision to discuss with a qualified healthcare provider.

What does genetic testing tell me about the GLP-1 class?

The Precision Peptide Genetic Test analyzes pathway-level variants in GLP1R, GIPR, FTO, MC4R, and other genes that may shape baseline GLP-1, incretin, appetite-regulation, and energy-balance biology. It does not predict response to a specific medication, but it can provide upstream context for a more informed provider conversation.

This article is part of the PlexusDx Education Hub. Browse all Peptides and GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.